期刊
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 22, 期 3, 页码 431-437出版社
MARY ANN LIEBERT INC
DOI: 10.1089/cbr.2006.321
关键词
alpha-emitting Th-227; radioimmunoconjugates
In this study, the feasibility, of constructing radioimmumoconjugates by using the novel therapeutic candidate alpha-emitter, Th-227, was evaluated. By use of the bifunctional chelator, p-SCN-benzyl-DOT, 227 was conjugated to the two monoclonal antibodies, rituximab and trastuzumab. Their stability in 80% fetal bovine serum at 37 degrees C was measured. The immunoreactive fractions were determined by using CD20-and HER/2-positive cells, respectively. The overall labeling yield spanned from 6% to 17%. The radiomimmununoconjugates demonstrated a relevant stability in serum and showed appropriate antigen-binding abilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据